Literature DB >> 7620016

Q fever in the Greek Island of Crete: epidemiologic, clinical, and therapeutic data from 98 cases.

Y Tselentis1, A Gikas, D Kofteridis, E Kyriakakis, N Lydataki, D Bouros, N Tsaparas.   

Abstract

A retrospective study was undertaken in Crete, Greece, to investigate the epidemiologic, clinical, and therapeutic aspects of Q fever. Over a period of 5 years (1989-1993), 1,298 patients were examined and 98 cases were identified. Individuals who were aged 20-29 years and 30-39 years appeared to have an increased risk of infection. Contact with animals was found to be a major risk factor for acquisition of Q fever. The predominant clinical manifestations of the infection were fever (91.7% of patients) and respiratory disease (88.5%), whereas hepatitis was the dominant feature in only a minority (7.1%) of patients. Chest radiographs frequently revealed pulmonary interstitial changes (36.4% of patients) and alveolar changes (34.4%). Abnormal echocardiographic findings were also observed. There was no difference in the duration of fever whether the patient received therapy with tetracycline or erythromycin, a finding that may be explained by the delay in initiating tetracycline therapy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7620016     DOI: 10.1093/clinids/20.5.1311

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  20 in total

1.  Coxiella burnetii and milk pasteurization: an early application of the precautionary principle?

Authors:  O Cerf; R Condron
Journal:  Epidemiol Infect       Date:  2006-02-22       Impact factor: 2.451

2.  Epidemiological study of Q fever in humans, ruminant animals, and ticks in Cyprus using a geographical information system.

Authors:  A Psaroulaki; C Hadjichristodoulou; F Loukaides; E Soteriades; A Konstantinidis; P Papastergiou; M C Ioannidou; Y Tselentis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-09       Impact factor: 3.267

3.  Q Fever endocarditis: does serology predict outcome?

Authors:  Arístides de Alarcón
Journal:  Curr Infect Dis Rep       Date:  2012-08       Impact factor: 3.725

4.  Newer macrolides as empiric treatment for acute Q fever infection.

Authors:  A Gikas; D P Kofteridis; A Manios; J Pediaditis; Y Tselentis
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

5.  In vitro susceptibility of Coxiella burnetii to linezolid in comparison with its susceptibilities to quinolones, doxycycline, and clarithromycin.

Authors:  A Gikas; I Spyridaki; E Scoulica; A Psaroulaki; Y Tselentis
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

6.  Epidemiological features of Mediterranean spotted fever, murine typhus, and Q fever in Split-Dalmatia County (Croatia), 1982-2002.

Authors:  V Punda-Polić; B Luksić; V Capkun
Journal:  Epidemiol Infect       Date:  2007-09-13       Impact factor: 2.451

7.  Unusual causes of intrahepatic cholestatic liver disease.

Authors:  Elias E Mazokopakis; John A Papadakis; Diamantis P Kofteridis
Journal:  World J Gastroenterol       Date:  2007-03-28       Impact factor: 5.742

8.  Q fever in the Greek island of Crete: detection, isolation, and molecular identification of eight strains of Coxiella burnetii from clinical samples.

Authors:  I Spyridaki; A Gikas; D Kofteridis; A Psaroulaki; Y Tselentis
Journal:  J Clin Microbiol       Date:  1998-07       Impact factor: 5.948

9.  In vitro susceptibility of Coxiella burnetii to trovafloxacin in comparison with susceptibilities to pefloxacin, ciprofloxacin, ofloxacin, doxycycline, and clarithromycin.

Authors:  A Gikas; I Spyridaki; A Psaroulaki; D Kofterithis; Y Tselentis
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191

10.  Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.

Authors:  Ioanna Spyridaki; Anna Psaroulaki; Iosif Vranakis; Yannis Tselentis; Achilleas Gikas
Journal:  Antimicrob Agents Chemother       Date:  2009-03-30       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.